Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 09/19 03:27:04 pm
82.545 EUR   +1.26%
02:33p SANOFI : and Regeneron Announce Positive Study Results for Dupixent ..
09/18 SANOFI : Disclosure of trading in own shares
09/18 SANOFI : Disclosure of trading in own shares
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
02:33p SANOFI : and Regeneron Announce Positive Study Results for Dupixent in Patients ..
09/18 SANOFI : Disclosure of trading in own shares
09/18 SANOFI : Disclosure of trading in own shares
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/16 SANOFI : Aventis Ukraine seeks to file claim to international court to protect i..
09/16 SANOFI : and Regeneron Announce Positive Study Results for Dupixent® (dupilumab)..
09/16 SANOFI : Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dup..
09/16 SANOFI : and Regeneron Announce Positive Study Results for Dupixent® (dupilumab)..
09/15 KERYX BIOPHARMACEUTICALS : Announces Changes to its Board of Directors
More news
News from SeekingAlpha
09/18 Sanofi (SNY) Presents At Bank of America Merrill Lynch 2017 Global Healthcare..
09/18 Regeneron and Sanofi's Dupixent shows positive effect in dermatitis patients ..
09/18 NOVARTIS : The Value Creator
09/16 Stocks to watch next week
09/14 Amgen Needs To Get Lucky With Repatha
Financials (€)
Sales 2017 36 307 M
EBIT 2017 9 642 M
Net income 2017 7 849 M
Debt 2017 5 108 M
Yield 2017 3,74%
P/E ratio 2017 13,24
P/E ratio 2018 17,23
EV / Sales 2017 2,98x
EV / Sales 2018 2,89x
Capitalization 103 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,2 €
Spread / Average Target 5,8%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI5.81%123 374
JOHNSON & JOHNSON16.70%363 360
NOVARTIS11.20%223 865
ROCHE HOLDING LTD.4.56%219 130
PFIZER9.45%211 705
MERCK AND COMPANY12.38%179 978